Bengaluru (ISJ) - India?s biopharma major Biocon Limited has developed a drug to treat psoriasis effectively. The drug named ?AlzuMAb?, the company claims, will address ?a large unmet need for the treatment of moderate-to-severe psoriasis in India?. ?AlzuMAb? or Itolizumab is the first anti-CD6 monoclonal antibody to be commercialized. Biocon?s Chairperson and Managing Director Kiran Mazumdar-Shaw said, it has a potential to treat multiple autoimmune diseases like rheumatoid arthritis, psoriatic arthritis and multiple sclerosis. She said, this innovative and affordable treatment option will be available to two per cent of Indian population, suffering from psoriasis. Psoriasis ? formation of red patches on skin ? is a chronic condition and does not have an effective cure. It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis is not contagious. There are five types of Psoriasis. The most common ? plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells. It can develop on any part of the body and is associated with other serious health conditions, such as diabetes, heart diseases and depression. Biocon?s President-Marketing Rakesh Bamzai said AlzuMAb?s longer remission periods and lower infection rates will lead to better patient compliance and overall reduction in the cost burden to the patient. He said, a single dose of AlzuMAb is priced at Rs. 7,950 and the person suffering from psoriasis has to undergo treatment for 24 weeks. The company plans to offer the drug in Indian market, but has moved the US Food and Drug Administration and European Medicine Agency for approval. The global psoriasis market size is estimated to cross 8 billion US dollars, said Shaw.
India?s Biocon unveils psoriasis drug